Psychosomatic Intervention in Fibromyalgia.
- Disease/Condition
- Fibromyalgia
- Drug/Device/Intervention
- psychosomatic intervention based on cognitive restructuring.
- Study type
- Interventional
- Intervention type
- other
- Primary sponsor
- University of Florence
- Location
- Firenze, Italy
- Phase
- N/A
- Start date
- Nov 01, 2023
- End date
- Dec 30, 2026
- Enrollment
- 100 participants
Psychosomatic status,Level of distress, well-being and quality of life
Fibromyalgia is a widespread musculoskeletal pain syndrome. It is characterized by physical
 manifestations which are also the expression of a psychological distress as well as specific
 illness attitudes and behaviors. Indeed, it is considered a psychosomatic disorder. In this
 framework, we hypothesize the clinical utility of a psychosomatic assessment guided by
 rheumatologists and clinical psychologists (Study 1) and the utility of an integrated
 multidisciplinary psychosomatic intervention based on cognitive restructuring/psychoeducation
 followed by museum therapy (Study 2). For Study 1 a cross-sectional observation study will be
 implemented, for Study 2 a randomized controlled trial will be applied.
- Registry
- ClinicalTrials.gov
- Trial ID
- NCT06135753
- Type
- Non-Device Trial
Access comprehensive clinical trial information for NCT06135753 through Pure Global AI's free database. This phase not specified trial is sponsored by University of Florence and is currently Recruiting. The study focuses on Fibromyalgia. Target enrollment is 100 participants.
This page provides complete trial specifications, intervention details, outcomes, and location information. Pure Global AI offers free access to ClinicalTrials.gov data, helping medical device and pharmaceutical companies navigate clinical research efficiently.